News Biotech and big pharma heading for a M&A filled 2018 After a relatively quiet 12 months for mergers and acquisitions in 2017, this year is expected to produce a bumper crop of deals between big pharma and biotech.
News Johnson & Johnson back in 'exclusive' talks to buy Actelion Deal expected to be worth around $30 billion.
News BIND accepts Pfizer bid following bankruptcy Bid of $20 million may be enough to acquire all of BIND's assets.
Articles Celgene’s new CEO weighs in to drug pricing debate Celgene's new CEO Mark Alles discusses pricing and M&A, criticises Valeant's approach. Richard Staines reports.
Digital Chaos & opportunity: Dr Adam Brown unpacks US health policy Dive into our video interview with Dr Adam Brown as he unpacks the chaos and opportunity shaping US health policy.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
